Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.

Purpose: To quantify the hepatic safety of pazopanib and comparator anti-vascular endothelial growth factor (VEGF) therapies in clinical practice among renal cell carcinoma (RCC) patients.Methods: A population-based cohort study of new anti-VEGF users was conducted in two US healthcare databases, De...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancer Chemotherapy & Pharmacology Vol. 78; no. 3; pp. 559 - 567
Autores principales:	Shantakumar, Sumitra, Nordstrom, Beth, Djousse, Luc, Hall, Susan, Gagnon, David, Fraeman, Kathy, Herk-Sukel, Myrthe, Chagin, Karen, Nelson, Jeanenne, Nordstrom, Beth L, Hall, Susan A, Gagnon, David R, Fraeman, Kathy H, van Herk-Sukel, Myrthe
Formato:	research Journal Article
Publicado:	Springer Nature Sep2016
Acceso en línea:	Ver este registro en EBSCOhost